메뉴 건너뛰기




Volumn 33, Issue 1, 2004, Pages 1-6

Selective cyclooxygenase-2 inhibitors: Similarities and differences

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ARYLACETIC ACID DERIVATIVE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DEXTROMETHORPHAN; DICLOFENAC; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESTROGEN; ETORICOXIB; GESTAGEN; IBUPROFEN; INDOMETACIN; LUMIRACOXIB; METHOTREXATE; METOPROLOL; NAPROXEN; NEUROLEPTIC AGENT; PARECOXIB; ROFECOXIB; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SULFONAMIDE; SULINDAC; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALDECOXIB; WARFARIN;

EID: 1542297649     PISSN: 03009742     EISSN: None     Source Type: Journal    
DOI: 10.1080/03009740310004766     Document Type: Review
Times cited : (118)

References (47)
  • 1
    • 0025871150 scopus 로고
    • TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue
    • Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266:12866-72.
    • (1991) J Biol Chem , vol.266 , pp. 12866-12872
    • Kujubu, D.A.1    Fletcher, B.S.2    Varnum, B.C.3    Lim, R.W.4    Herschman, H.R.5
  • 2
    • 0025754779 scopus 로고
    • Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing
    • Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692-6.
    • (1991) Proc Natl Acad Sci USA , vol.88 , pp. 2692-2696
    • Xie, W.L.1    Chipman, J.G.2    Robertson, D.L.3    Erikson, R.L.4    Simmons, D.L.5
  • 5
    • 0026588059 scopus 로고
    • Prostaglandin endoperoxide synthase gene structure: Identification of the transcriptional start site and 5′-flanking regulatory sequences
    • Kraemer SA, Meade EA, DeWitt DL. Prostaglandin endoperoxide synthase gene structure: identification of the transcriptional start site and 5′-flanking regulatory sequences. Arch Biochem Biophys 1992;293:391-400.
    • (1992) Arch Biochem Biophys , vol.293 , pp. 391-400
    • Kraemer, S.A.1    Meade, E.A.2    DeWitt, D.L.3
  • 7
    • 0030597962 scopus 로고    scopus 로고
    • Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation
    • Beiche F, Scheuerer S, Brune K, Geisslinger G, Goppelt-Struebe M. Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett 1996;390:165-9.
    • (1996) FEBS Lett , vol.390 , pp. 165-169
    • Beiche, F.1    Scheuerer, S.2    Brune, K.3    Geisslinger, G.4    Goppelt-Struebe, M.5
  • 8
    • 0028034970 scopus 로고
    • Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction
    • Harris RC, McKanna JA, Akai Y, Jacobson HR, Dubois RN, Breyer MD. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest 1995;94:2504-10.
    • (1995) J Clin Invest , vol.94 , pp. 2504-2510
    • Harris, R.C.1    McKanna, J.A.2    Akai, Y.3    Jacobson, H.R.4    Dubois, R.N.5    Breyer, M.D.6
  • 10
    • 0036156424 scopus 로고    scopus 로고
    • Cyclooxygenase-2-10 years later
    • Hinz B, Brune K. Cyclooxygenase-2-10 years later. J Pharmacol Exp Ther 2002;300:367-75.
    • (2002) J Pharmacol Exp Ther , vol.300 , pp. 367-375
    • Hinz, B.1    Brune, K.2
  • 11
    • 0031456454 scopus 로고    scopus 로고
    • Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs
    • Patrignani P, Panara MR, Sciulli MG, Santini G, Renda G, Patrono C. Differential inhibition of human prostaglandin endoperoxide synthase-1 and -2 by nonsteroidal anti-inflammatory drugs. J Physiol Pharmacol 1997;48:623-31.
    • (1997) J Physiol Pharmacol , vol.48 , pp. 623-631
    • Patrignani, P.1    Panara, M.R.2    Sciulli, M.G.3    Santini, G.4    Renda, G.5    Patrono, C.6
  • 12
  • 13
    • 0034093534 scopus 로고    scopus 로고
    • Celecoxib: A review of its use in osteoarthritis, rheumatoid arthritis and acute pain
    • Clemett D, Goa KL. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000;59:957-80.
    • (2000) Drugs , vol.59 , pp. 957-980
    • Clemett, D.1    Goa, K.L.2
  • 14
    • 0034944053 scopus 로고    scopus 로고
    • Parecoxib
    • Cheer SM, Goa KL. Parecoxib. Drugs 2001;61:1133-41.
    • (2001) Drugs , vol.61 , pp. 1133-1141
    • Cheer, S.M.1    Goa, K.L.2
  • 15
    • 0035833502 scopus 로고    scopus 로고
    • The coxibs, selective inhibitors of cyclooxygenase 2
    • Fitzgerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase 2. N Engl J Med 2001;345:433-42.
    • (2001) N Engl J Med , vol.345 , pp. 433-442
    • Fitzgerald, G.A.1    Patrono, C.2
  • 16
    • 0034955602 scopus 로고    scopus 로고
    • An update on specific COX-2 inhibitors: The COXIBs
    • Gupta S, Crofford LJ. An update on specific COX-2 inhibitors: the COXIBs. Bull Rheum Dis 2001;50:1-4.
    • (2001) Bull Rheum Dis , vol.50 , pp. 1-4
    • Gupta, S.1    Crofford, L.J.2
  • 19
    • 0041664973 scopus 로고    scopus 로고
    • Rofecoxib: An update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects
    • Ahuja N, Singh A, Sing B. Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects. J Pharm Pharmacol 2003;55:859-94.
    • (2003) J Pharm Pharmacol , vol.55 , pp. 859-894
    • Ahuja, N.1    Singh, A.2    Sing, B.3
  • 21
    • 0037329781 scopus 로고    scopus 로고
    • Clinical pharmacology of etoricoxib: A novel selective COX-2 inhibitor
    • Patrignani P, Capone ML, Tacconelli S. Clinical pharmacology of etoricoxib: a novel selective COX-2 inhibitor. Expert Opin Phamacother 2003;4:265-74.
    • (2003) Expert Opin Phamacother , vol.4 , pp. 265-274
    • Patrignani, P.1    Capone, M.L.2    Tacconelli, S.3
  • 23
    • 0012762428 scopus 로고    scopus 로고
    • The in vitro and in vivo selectivity of COX189, a new and highly selective inhibitor of COX-2
    • abstract SAT 0013
    • Marshall PJ, Berry C, Wasvary J, Van Duzer J, Du Z, Scott G, et al. The in vitro and in vivo selectivity of COX189, a new and highly selective inhibitor of COX-2 (abstract SAT 0013). Ann Rheum Dis 2002;61. (Suppl):S259.
    • (2002) Ann Rheum Dis , vol.61 , Issue.SUPPL.
    • Marshall, P.J.1    Berry, C.2    Wasvary, J.3    Van Duzer, J.4    Du, Z.5    Scott, G.6
  • 24
    • 0033665248 scopus 로고    scopus 로고
    • Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: A randomized, controlled trial
    • Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol 2000;40:124-32.
    • (2000) J Clin Pharmacol , vol.40 , pp. 124-132
    • Leese, P.T.1    Hubbard, R.C.2    Karim, A.3    Isakson, P.C.4    Yu, S.S.5    Geis, G.S.6
  • 25
    • 0017279930 scopus 로고
    • Mechanism of action of anti-inflammatory drugs
    • Brune K, Glatt M, Graf P. Mechanism of action of anti-inflammatory drugs. Gen Pharmacol 1976;7:27-33.
    • (1976) Gen Pharmacol , vol.7 , pp. 27-33
    • Brune, K.1    Glatt, M.2    Graf, P.3
  • 27
    • 0036163827 scopus 로고    scopus 로고
    • Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry
    • Werner U, Werner D, Pahl A, Mundkowski R, Gillich M, Brune K. Investigation of the pharmacokinetics of celecoxib by liquid chromatography-mass spectrometry. Biomed Chromatogr 2002;16:56-60.
    • (2002) Biomed Chromatogr , vol.16 , pp. 56-60
    • Werner, U.1    Werner, D.2    Pahl, A.3    Mundkowski, R.4    Gillich, M.5    Brune, K.6
  • 28
    • 0042126736 scopus 로고    scopus 로고
    • Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans
    • Werner U, Werner D, Rau T, Fromm MF, Hinz B, Brune K. Celecoxib inhibits metabolism of cytochrome P450 2D6 substrate metoprolol in humans. Clin Pharmacol Ther 2003;74:130-7.
    • (2003) Clin Pharmacol Ther , vol.74 , pp. 130-137
    • Werner, U.1    Werner, D.2    Rau, T.3    Fromm, M.F.4    Hinz, B.5    Brune, K.6
  • 29
    • 0034805254 scopus 로고    scopus 로고
    • Rofecoxib versus codeine/acetaminophen in post-operative dental pain: A double-blind, randomized, placebo- and active comparator-controlled clinical trial
    • Chang DJ, Fricke JR, Bird SR, Bohidar NR, Dobbins TW, Geba GP. Rofecoxib versus codeine/acetaminophen in post-operative dental pain: a double-blind, randomized, placebo- and active comparator-controlled clinical trial. Clin Ther 2001;23:1446-55.
    • (2001) Clin Ther , vol.23 , pp. 1446-1455
    • Chang, D.J.1    Fricke, J.R.2    Bird, S.R.3    Bohidar, N.R.4    Dobbins, T.W.5    Geba, G.P.6
  • 31
    • 0035000968 scopus 로고    scopus 로고
    • Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor
    • Kassahun K, McIntosh IS, Shou M, Walsh DJ, Rodeheffer C, Slaughter DE, et al. Role of human liver cytochrome P4503A in the metabolism of etoricoxib, a novel cyclooxygenase-2 selective inhibitor. Drug Metab Dispos 2001;29:813-20.
    • (2001) Drug Metab Dispos , vol.29 , pp. 813-820
    • Kassahun, K.1    McIntosh, I.S.2    Shou, M.3    Walsh, D.J.4    Rodeheffer, C.5    Slaughter, D.E.6
  • 32
    • 0035949182 scopus 로고    scopus 로고
    • Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humans
    • Werner U, Werner D, Mundkowski R, Gillich M, Brune K. Selective and rapid liquid chromatography-mass spectrometry method for the quantification of rofecoxib in pharmacokinetic studies with humans. J Chromatogr B Biomed Sci Appl 2001;760:83-90.
    • (2001) J Chromatogr B Biomed Sci Appl , vol.760 , pp. 83-90
    • Werner, U.1    Werner, D.2    Mundkowski, R.3    Gillich, M.4    Brune, K.5
  • 33
    • 0141771315 scopus 로고    scopus 로고
    • Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects
    • abstract 281
    • Mangold JB, Gu H, Rodriguez LC, Scott G, Bonner J, Rordorf C. Pharmacokinetics and metabolism of lumiracoxib in healthy male subjects (abstract 281). Drug Metab Rev 2002;34. (Supp):S141.
    • (2002) Drug Metab Rev , vol.34 , Issue.SUPPL.
    • Mangold, J.B.1    Gu, H.2    Rodriguez, L.C.3    Scott, G.4    Bonner, J.5    Rordorf, C.6
  • 34
    • 2042457058 scopus 로고    scopus 로고
    • Lumiracoxib demonstrates high absolute bioavailability in healthy subjects
    • abstract P-199. Tulunay FC, Orme M, editors. European collaboration: Towards drug development and rational drug therapy. 2003 June 24-28, Istanbul, Turkey. Berlin: Springer-Verlag
    • Hartmann S, Scott G, Rordorf C, Campestrini J, Branson J, Keller U. Lumiracoxib demonstrates high absolute bioavailability in healthy subjects (abstract P-199). In: Tulunay FC, Orme M, editors. European collaboration: Towards drug development and rational drug therapy. Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics.; 2003 June 24-28, Istanbul, Turkey. Berlin: Springer-Verlag; 2003.
    • (2003) Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics
    • Hartmann, S.1    Scott, G.2    Rordorf, C.3    Campestrini, J.4    Branson, J.5    Keller, U.6
  • 35
    • 1542330813 scopus 로고    scopus 로고
    • Lumiracoxib does not alter the pharmacokinetic profile or efficacy of the triphasic oral contraceptive Triphasil-28
    • abstract P-198. Tulunay FC, Orme M, editors. European collaboration: Towards drug development and rational drug therapy. 2003 June 24-28, Istanbul, Turkey. Berlin: Springer-Verlag
    • Kalbag J, Rordorf C, Wang Y, Caldwell J, Leese P, Scott G. Lumiracoxib does not alter the pharmacokinetic profile or efficacy of the triphasic oral contraceptive Triphasil-28 (abstract P-198). In: Tulunay FC, Orme M, editors. European collaboration: Towards drug development and rational drug therapy. Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics.; 2003 June 24-28, Istanbul, Turkey. Berlin: Springer-Verlag; 2003.
    • (2003) Proceedings of the Sixth Congress of the European Association for Clinical Pharmacology and Therapeutics
    • Kalbag, J.1    Rordorf, C.2    Wang, Y.3    Caldwell, J.4    Leese, P.5    Scott, G.6
  • 36
    • 0034707105 scopus 로고    scopus 로고
    • Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
    • VIGOR Study Group
    • Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-8.
    • (2000) N Engl J Med , vol.343 , pp. 1520-1528
    • Bombardier, C.1    Laine, L.2    Reicin, A.3    Shapiro, D.4    Burgos-Vargas, R.5    Davis, B.6
  • 37
    • 0034644396 scopus 로고    scopus 로고
    • Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial
    • Celecoxib Long-term Arthritis Safety Study
    • Silverstein FE, Faich G. Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. [Celecoxib Long-term Arthritis Safety Study.] J Am Med Assoc 2000;284:1247-55.
    • (2000) J Am Med Assoc , vol.284 , pp. 1247-1255
    • Silverstein, F.E.1    Faich, G.2    Goldstein, J.L.3    Simon, L.S.4    Pincus, T.5    Whelton, A.6
  • 38
    • 0034811819 scopus 로고    scopus 로고
    • Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo
    • Harris SI, Kuss M, Hubbard RC, Goldstein JL. Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2- specific inhibitor, compared with ketorolac, naproxen, and placebo. Clin Ther 2001;23:1422-8.
    • (2001) Clin Ther , vol.23 , pp. 1422-1428
    • Harris, S.I.1    Kuss, M.2    Hubbard, R.C.3    Goldstein, J.L.4
  • 39
    • 0036794967 scopus 로고    scopus 로고
    • Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis
    • Sikes DH, Agrawal NM, Zhao WW, Kent JD, Recker DP, Verburg KM. Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. Eur J Gastroenterol Hepatol 2002;14:1101-11.
    • (2002) Eur J Gastroenterol Hepatol , vol.14 , pp. 1101-1111
    • Sikes, D.H.1    Agrawal, N.M.2    Zhao, W.W.3    Kent, J.D.4    Recker, D.P.5    Verburg, K.M.6
  • 40
    • 0141852139 scopus 로고    scopus 로고
    • Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: A pilot endoscopic study in healthy male subjects
    • Rordorf C, Kellett N, Mair S, Ford M, Milosavljev S, Branson J, Scott G. Gastroduodenal tolerability of lumiracoxib vs placebo and naproxen: a pilot endoscopic study in healthy male subjects. Aliment Pharmacol Ther 2003;18:533-41.
    • (2003) Aliment Pharmacol Ther , vol.18 , pp. 533-541
    • Rordorf, C.1    Kellett, N.2    Mair, S.3    Ford, M.4    Milosavljev, S.5    Branson, J.6    Scott, G.7
  • 41
    • 0033050264 scopus 로고    scopus 로고
    • Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation
    • Wallace JL, Chapman K, McKnight W. Limited anti-inflammatory efficacy of cyclo-oxygenase-2 inhibition in carrageenan-airpouch inflammation. Br J Pharmacol 1999;126:1200-4.
    • (1999) Br J Pharmacol , vol.126 , pp. 1200-1204
    • Wallace, J.L.1    Chapman, K.2    McKnight, W.3
  • 42
    • 0036967076 scopus 로고    scopus 로고
    • Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation
    • Pinheiro RM, Calixto JB. Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation. Inflamm Res 2002;51:603-10.
    • (2002) Inflamm Res , vol.51 , pp. 603-610
    • Pinheiro, R.M.1    Calixto, J.B.2
  • 43
    • 0036100771 scopus 로고    scopus 로고
    • Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclooxygenase-2-selective inhibitors in patients with rheumatoid arthritis
    • Knijff-Dutmer EA, Kalsbeek-Batenburg EM, Koerts J, van de Laar MA. Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclooxygenase-2-selective inhibitors in patients with rheumatoid arthritis. Rheumatology 2002;41:458-61.
    • (2002) Rheumatology , vol.41 , pp. 458-461
    • Knijff-Dutmer, E.A.1    Kalsbeek-Batenburg, E.M.2    Koerts, J.3    Van De Laar, M.A.4
  • 44
    • 0037322970 scopus 로고    scopus 로고
    • Strategies in pain management: New and potential indications for COX-2 specific inhibitors
    • Ruoff G, Lema M. Strategies in pain management: new and potential indications for COX-2 specific inhibitors. J Pain Symptom Manage 2003;25(Suppl):S21-31.
    • (2003) J Pain Symptom Manage , vol.25 , Issue.SUPPL.
    • Ruoff, G.1    Lema, M.2
  • 46
    • 0036219338 scopus 로고    scopus 로고
    • The mechanism of action of the new antiinflammatory compound ML3000: Inhibition of 5-LOX and COX-1/2
    • Tries S, Neupert W, Laufer S. The mechanism of action of the new antiinflammatory compound ML3000: inhibition of 5-LOX and COX-1/2. Inflamm Res 2002;51:135-43.
    • (2002) Inflamm Res , vol.51 , pp. 135-143
    • Tries, S.1    Neupert, W.2    Laufer, S.3
  • 47
    • 0036562261 scopus 로고    scopus 로고
    • Potential cardioprotective actions of NO-releasing aspirin
    • Wallace JL, Ignarro LJ, Fiorucci S. Potential cardioprotective actions of NO-releasing aspirin. Nat Rev Drug Discov 2002;1:375-82.
    • (2002) Nat Rev Drug Discov , vol.1 , pp. 375-382
    • Wallace, J.L.1    Ignarro, L.J.2    Fiorucci, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.